Charlottesville, VA – January 4, 2011 – Biovista Inc., a privately held drug discovery company focused on finding novel uses for existing drugs, announced today that Aris Persidis, Ph.D, president and co-founder of Biovista, will be presenting at the 4th Annual OneMedForum 2011 conference. Dr. Persidis’ presentation will be given at the Sir Francis Drake Hotel in the Franciscan Room in San Francisco on Tuesday, January 11, 2011 at 1:55 p.m. PST.
Additionally, Dr. Persidis will be presenting at the Biotech Showcase™ 2011 conference. Dr. Persidis’ presentation will be given at the Parc 55 Hotel in the Mission I Room in San Francisco on Wednesday, January 12, 2011 at 2 p.m. PST. Both presentations will include an overview of COSS (the company’s discovery platform), drug pipeline and methods of collaboration.
In January 2010, Biovista and the Food & Drug Administration’s (FDA’s) Office of Clinical Pharmacology (OCP) announced a research collaboration to profile the safety of drugs of interest to FDA/OCP.
In November 2010, Pfizer entered into an initial research collaboration agreement with Biovista to expand the indication footprint of selected drugs. This collaboration includes an up-front payment to Biovista and success-based milestones.
Biovista has developed its own pipeline of more than 60 repositioned generic compounds for various indications, including MS, epilepsy, glioblastoma multiforme and melanoma.
Facts About Biovista:
Biovista, Inc. focuses on finding alternative uses for existing compounds, and on profiling the adverse effects (AE) of drugs in or before clinical trials. The company performs most of its research through COSS, the company’s proprietary drug research platform that correlates the mechanism of action (MoA) of a drug against the MoA of 23,000 diseases, 95,000 cataloged drugs, and 6,000 AEs.